What Researchers Did
Researchers gave adults with high-grade brain tumours (gliomas) radiotherapy right after a hyperbaric oxygen session, together with three chemotherapy drugs, and followed them over the long term.
What They Found
In a Phase II clinical trial of 57 adults with high-grade gliomas, radiotherapy given right after hyperbaric oxygen (HBO) plus chemotherapy was completed by all patients, and median overall survival was 20.2 months for the whole group. Survival was 17.2 months for the 39 patients with glioblastoma and 113.4 months for the 18 patients with Grade 3 gliomas. Tumour grade was the only significant factor linked to survival (p less than 0.001). No patient had neutropenic fever or intracranial hemorrhage, and no serious non-blood-related or late toxicities were seen. Twelve patients were still alive at a median follow-up of 62.0 months.
What This Means for Canadian Patients
For people with high-grade gliomas, this trial shows that radiotherapy (60 Gy in daily 2 Gy fractions) delivered less than 15 minutes after HBO, with chemotherapy, could be completed and had few serious side effects. The trial had no comparison group, so it cannot show whether HBO changed survival. Survival in glioblastoma was much shorter than in Grade 3 gliomas. Anyone considering this approach should discuss it with their cancer care team.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This was a single-group Phase II trial with no comparison group, so the abstract cannot show that HBO improved survival, and only 12 of the 57 patients were alive at the last follow-up.